Don't Overlook Ziopharm Oncology

 | Mar 20, 2017 | 11:23 AM EDT
  • Comment
  • Print Print
  • Print
Stock quotes in this article:

ziop

Ziopharm Oncology (ZIOP) is a low-priced stock that could get passed over for bigger and better-known names in the industry, but the charts and indicators are intriguing enough to write about it.

This stock could rally 50% or more in the months ahead, which is not a bad rate of return.

In this daily bar chart of ZIOP, above, we can see prices have been bottoming since July. You should be able to see the higher lows from July to October to January and February. You should also be able to see lower highs from November to February and March. The chart pattern since November could be considered a triangle and it is close to its apex and a potential upside breakout. ZIOP is above it rising 50-day moving average line and the still-declining 200-day moving average. The On-Balance-Volume (OBV) line has shown some improvement from a January low. The MACD oscillator is above the zero line and could soon cross to a fresh go-long signal.

In this Point and Figure chart of ZIOP, above, we can see a bullish-looking pattern since early 2016. A move above $7 on the daily bar chart and a trade at $7.20 on this Point and Figure chart should be good enough to break a longer-term downtrend and generate a breakout with an upside move to the $10 area.

Bottom line: Traders could go long ZIOP above $7 and add above $7.20. After going long above $7, a sell-stop below $6 should work. Our initial upside price objective is $10.

Columnist Conversations

our chart of the week worked out nicely! we'll bank this big winner and roll up SOLD BIIB AUG 270 CALL AT...
No news yet, but Ralph Lauren (RL) is surging in early trading. Shares that previously traded as hi...
Good morning. Just a few comments about stocks that are in the news. Forget what I said about Chinese Inter...
Just what is the Fed thinking about these days?  Let's talk about it at 130pm PST (430pm EST), free to at...

BEST IDEAS

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.